Compare MKS Instruments (MKSI) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MKS Instruments vs Repligen Corporation Common Stock — how do they compare? MKS Instruments trades at $230.19 (market cap $16.74B), while Repligen Corporation Common Stock trades at $178.18 (market cap $11.14B). The key difference: MKS Instruments is the larger of the two by market cap, and MKS Instruments pays a 0.4% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold MKS Instruments for 9 Days and Repligen Corporation Common Stock for 0 Days on average.
| MKSI | RGEN | |
|---|---|---|
Market Cap | $16.74B | $11.14B |
Volume | 1,685,097 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $444.80 | $194.57 |
52-Week Low | $134.42 | $102.87 |
Typical Hold Time | 9 Days | 0 Days |
Enterprise Value | $20.31B | $11.02B |
Dividend Yield | 0.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MKSI trades at $247.56, down 0.94% on the day, with a bearish technical signal despite strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $3.30 exceeding expectations by 13.4%. Revenue growth continues with 2026 projections showing $4.3B and net profit margin expanding to 10.09%. Analyst consensus remains strongly bullish with 82.8% buy ratings and a $404 price target representing 63% upside potential.
The stock presents compelling growth potential driven by earnings momentum and institutional confidence, though near-term technical weakness and margin pressures from facility expansions pose risks. Long-term wafer fabrication equipment demand and ESG initiatives provide strategic tailwinds, but investors should monitor execution on profitability targets amid competitive pressures in the electronics sector.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MKS Instruments
MKS develops instruments, systems, and process control solutions for advanced manufacturing. Its technologies serve semiconductor manufacturing, electronics and packaging, photonics, and specialty industrial applications.
Read more on MKSI →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
